Literature DB >> 9528838

Correlation between basic fibroblast growth factor immunostaining of stromal cells and stromelysin-3 mRNA expression in human breast carcinoma.

C Linder1, P Byström, G Engel, G Auer, U Aspenblad, H Strander, S Linder.   

Abstract

We examined the localization of basic fibroblast growth factor (bFGF) in a series of human breast carcinomas using immunohistochemistry. Staining was observed in tumour cells in 15 out of 54 (28%) tumours and in the adjacent stroma in 34 out of 54 (63%) tumours examined. No correlation was observed between positive staining of these two compartments. The relationship between bFGF staining and expression of the metalloprotease stromelysin-3, and between bFGF and microvessel density, was examined. A statistically significant correlation (P < 0.003) was observed between bFGF staining of the stromal compartment and high expression of stromelysin-3 (ST-3; MMP-11) metalloprotease mRNA by stromal cells. In contrast, no correlation was observed between bFGF and intratumour microvessel density (IMD). These results raise the possibility that bFGF may be involved in the induction of stromelysin-3 mRNA expression in breast cancer stroma.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9528838      PMCID: PMC2150112          DOI: 10.1038/bjc.1998.155

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  31 in total

1.  Correlation between stromelysin-3 mRNA level and outcome of human breast cancer.

Authors:  G Engel; K Heselmeyer; G Auer; M Bäckdahl; E Eriksson; S Linder
Journal:  Int J Cancer       Date:  1994-09-15       Impact factor: 7.396

2.  Stromelysin 3 belongs to a subgroup of proteinases expressed in breast carcinoma fibroblastic cells and possibly implicated in tumor progression.

Authors:  C Wolf; N Rouyer; Y Lutz; C Adida; M Loriot; J P Bellocq; P Chambon; P Basset
Journal:  Proc Natl Acad Sci U S A       Date:  1993-03-01       Impact factor: 11.205

3.  Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in breast cancer.

Authors:  L F Brown; B Berse; R W Jackman; K Tognazzi; A J Guidi; H F Dvorak; D R Senger; J L Connolly; S J Schnitt
Journal:  Hum Pathol       Date:  1995-01       Impact factor: 3.466

4.  Biologic and clinical significance of basic fibroblast growth factor immunostaining in breast carcinoma.

Authors:  D W Visscher; F DeMattia; S Ottosen; F H Sarkar; J D Crissman
Journal:  Mod Pathol       Date:  1995-08       Impact factor: 7.842

5.  Prognostic value of vascular endothelial growth factor expression in gastric carcinoma.

Authors:  K Maeda; Y S Chung; Y Ogawa; S Takatsuka; S M Kang; M Ogawa; T Sawada; M Sowa
Journal:  Cancer       Date:  1996-03-01       Impact factor: 6.860

6.  Inhibition of angiogenesis by tissue inhibitor of metalloproteinase.

Authors:  M D Johnson; H R Kim; L Chesler; G Tsao-Wu; N Bouck; P J Polverini
Journal:  J Cell Physiol       Date:  1994-07       Impact factor: 6.384

7.  Tumor cells secrete an angiogenic factor that stimulates basic fibroblast growth factor and urokinase expression in vascular endothelial cells.

Authors:  F A Peverali; S J Mandriota; P Ciana; R Marelli; P Quax; D B Rifkin; G Della Valle; P Mignatti
Journal:  J Cell Physiol       Date:  1994-10       Impact factor: 6.384

8.  Expression of basic fibroblast growth factor, FGFR1 and FGFR2 in normal and malignant human breast, and comparison with other normal tissues.

Authors:  Y A Luqmani; M Graham; R C Coombes
Journal:  Br J Cancer       Date:  1992-08       Impact factor: 7.640

9.  Comparative expression of fibroblast growth factor mRNAs in benign and malignant breast disease.

Authors:  S Y Anandappa; J H Winstanley; S Leinster; B Green; P S Rudland; R Barraclough
Journal:  Br J Cancer       Date:  1994-04       Impact factor: 7.640

10.  Association of vascular endothelial growth factor expression with tumor angiogenesis and with early relapse in primary breast cancer.

Authors:  M Toi; S Hoshina; T Takayanagi; T Tominaga
Journal:  Jpn J Cancer Res       Date:  1994-10
View more
  6 in total

Review 1.  Beyond VEGF: inhibition of the fibroblast growth factor pathway and antiangiogenesis.

Authors:  Christopher Lieu; John Heymach; Michael Overman; Hai Tran; Scott Kopetz
Journal:  Clin Cancer Res       Date:  2011-09-27       Impact factor: 12.531

2.  Structural and functional analysis of the Xestia c-nigrum granulovirus matrix metalloproteinase.

Authors:  R Ko; K Okano; S Maeda
Journal:  J Virol       Date:  2000-12       Impact factor: 5.103

Review 3.  Tyrosine kinase signalling in breast cancer: fibroblast growth factors and their receptors.

Authors:  C Dickson; B Spencer-Dene; C Dillon; V Fantl
Journal:  Breast Cancer Res       Date:  2000-03-25       Impact factor: 6.466

4.  Therapeutically targeting tumor microenvironment-mediated drug resistance in estrogen receptor-positive breast cancer.

Authors:  Kevin Shee; Wei Yang; John W Hinds; Riley A Hampsch; Frederick S Varn; Nicole A Traphagen; Kishan Patel; Chao Cheng; Nicole P Jenkins; Arminja N Kettenbach; Eugene Demidenko; Philip Owens; Anthony C Faber; Todd R Golub; Ravid Straussman; Todd W Miller
Journal:  J Exp Med       Date:  2018-02-07       Impact factor: 14.307

5.  Asporin is a stromally expressed marker associated with prostate cancer progression.

Authors:  Annie Rochette; Nadia Boufaied; Eleonora Scarlata; Lucie Hamel; Fadi Brimo; Hayley C Whitaker; Antonio Ramos-Montoya; David E Neal; Alice Dragomir; Armen Aprikian; Simone Chevalier; Axel A Thomson
Journal:  Br J Cancer       Date:  2017-02-02       Impact factor: 7.640

6.  Low interleukin-1alpha messenger RNA levels predict decreased overall survival time of patients with urinary bladder carcinoma.

Authors:  M Seddighzadeh; G Steineck; O Jansson; P Larsson; H Wijkström; J Adolfsson; N Portwood; J Hansson; S Linder
Journal:  Br J Cancer       Date:  2001-02-02       Impact factor: 7.640

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.